IDWeek 2026: New Exploratory Analyses Evaluate XOCOVA® (ensitrelvir) Following COVID-19 Exposure, Including Breakthrough Infections and Infection Present at Baseline
October 21, 2026 · 8:00 AM · OSAKA, Japan
Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) will present new exploratory analyses from the global Phase 3 SCORPIO-PEP study, virology data from across the ensitrelvir phase 3 program, and new insights on the continued burden of COVID-19 at IDWeek 2026. XOCOVA® (ensitrelvir) was approved in May 2026 by the U.S. Food and Drug Administration (FDA) for post-exposure prophylaxis (PEP) of COV...
- PublishedOctober 21, 2026 · 8:00 AM
- LocationOSAKA, Japan
- IndustryScience
- LanguageEN
Published by Business Wire. Read the original announcement for the full release.
Read the full announcement →